Kyowa Kirin Co., Ltd.
4151
주식 순위
#2444
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
주가
$15.32
시가총액
$8.02B
변동 (1일)
0.88%
변동 (1년)
2.20%
국가
JP
거래 Kyowa Kirin Co., Ltd. (4151)
카테고리
Healthcare
Kyowa Kirin Co., Ltd. (4151)의 수익
Jun 2026 기준 수익 TTM: $670.11M
Kyowa Kirin Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $670.11M입니다. 2024년에 회사는 $531.54M의 수익을 올렸으며 이는 2023년의 수익 $689.55M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Kyowa Kirin Co., Ltd.의 수익 기록 (2001 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $670.11M | 20.53% |
| 2025 | $555.99M | 4.60% |
| 2024 | $531.54M | -22.92% |
| 2023 | $689.55M | 33.80% |
| 2022 | $515.37M | -1.21% |
| 2021 | $521.68M | 3.05% |
| 2020 | $506.23M | 23.66% |
| 2019 | $409.36M | -38.89% |
| 2018 | $669.84M | 35.13% |
| 2017 | $495.69M | 91.40% |
| 2016 | $258.98M | -24.70% |
| 2015 | $343.93M | 51.18% |
| 2014 | $227.50M | -51.87% |
| 2013 | $472.68M | -9.21% |
| 2012 | $520.61M | -13.00% |
| 2011 | $598.40M | 14.88% |
| 2010 | $520.91M | 134.43% |
| 2009 | $222.20M | -42.92% |
| 2008 | $389.26M | 95.19% |
| 2007 | $199.42M | -5.68% |
| 2006 | $211.43M | -24.31% |
| 2005 | $279.35M | 89.18% |
| 2004 | $147.66M | 2.74% |
| 2003 | $143.72M | 52.82% |
| 2002 | $94.04M | -46.07% |
| 2001 | $174.37M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $33.60B | 4,913.43% |
US
|
|
| $17.74B | 2,546.87% |
US
|
|
| $8.70B | 1,198.14% |
US
|
|
| $5.95B | 787.61% |
US
|
|
| $21.39B | 3,091.75% |
CH
|
